Earnings Releases·Nov 6, 2026, 7:05 AM ET

Treace Medical Concepts — Third Quarter 2026 Earnings Summary

Q3 2026 revenue declined 4% to $48.3 million year-over-year, while net loss improved 23% to $12.6 million ($0.19/share) and Adjusted EBITDA turned positive at $0.3 million versus a $2.6 million loss in Q3 2025.
Full-year 2026 revenue guidance was lowered to $206–$210 million (1–3% decline YoY), though Adjusted EBITDA loss guidance tightened significantly to $1.0–$2.0 million from a prior range of $3.0–$5.0 million.
The company achieved double-digit procedure volume growth and market share gains, with 45% of Lapiplasty® users now adopting new bunion systems, despite revenue pressure from a shift toward lower-priced minimally invasive products.
Cash usage decreased 53% year-to-date to a $9.7 million reduction compared to 2025, with cash and marketable securities totaling $39.8 million and an additional $115 million borrowing capacity available.